中国临床药学杂志
中國臨床藥學雜誌
중국림상약학잡지
CHINESE JOURNAL OF CLINICAL PHARMACY
2008年
5期
262-264
,共3页
李向阳%顾芹%盛华%沈维敏
李嚮暘%顧芹%盛華%瀋維敏
리향양%고근%성화%침유민
布地奈德%慢性阻塞性肺疾病%肺功能%糖代谢
佈地奈德%慢性阻塞性肺疾病%肺功能%糖代謝
포지내덕%만성조새성폐질병%폐공능%당대사
budesonide%chronic obstructive pulmonary disease%pulmonary function%glycometabolism
目的 探讨布地奈德雾化吸入在慢性阻塞性肺疾病合并糖尿病患者中的疗效及对糖代谢的影响.方法 60例患者随机分成2组,布地奈德组予氧启动雾化吸入布地奈德混悬液2 mg,bid+异丙托溴铵雾化吸入液500μg,bid;对照组予氧启动雾化吸入异丙托溴铵雾化吸入液500μg.治疗前后测定肺功能一秒钟用力呼气容积(FEV1)、FEV1占预计值百分比(FEV1%),动脉血氧分压(PaO2),及血糖(FPG),糖化血红蛋白(HbA1c).结果 57例完成试验,治疗3 mo后,布地奈德组FEV1由(1.27±0.20)L升至(1.49±0.21)L(P＜0.01),FEV1%由(64.14±6.37)升至(74.76±7.62),(P＜0.01),和对照组相比差异有统计学意义(P＜0.05),治疗6 mo后的FEV1、FEV1%和3 mo相比差异无统计学意义(P＞0.05).布地奈德组FPG、HbA1c治疗前后差异无统计学意义(P＞0.05).结论 在慢性阻塞性肺疾病合并糖尿病患者中,布地奈德雾化吸入治疗3-6 mo可改善肺通气功能,而对于血糖则无影响.
目的 探討佈地奈德霧化吸入在慢性阻塞性肺疾病閤併糖尿病患者中的療效及對糖代謝的影響.方法 60例患者隨機分成2組,佈地奈德組予氧啟動霧化吸入佈地奈德混懸液2 mg,bid+異丙託溴銨霧化吸入液500μg,bid;對照組予氧啟動霧化吸入異丙託溴銨霧化吸入液500μg.治療前後測定肺功能一秒鐘用力呼氣容積(FEV1)、FEV1佔預計值百分比(FEV1%),動脈血氧分壓(PaO2),及血糖(FPG),糖化血紅蛋白(HbA1c).結果 57例完成試驗,治療3 mo後,佈地奈德組FEV1由(1.27±0.20)L升至(1.49±0.21)L(P＜0.01),FEV1%由(64.14±6.37)升至(74.76±7.62),(P＜0.01),和對照組相比差異有統計學意義(P＜0.05),治療6 mo後的FEV1、FEV1%和3 mo相比差異無統計學意義(P＞0.05).佈地奈德組FPG、HbA1c治療前後差異無統計學意義(P＞0.05).結論 在慢性阻塞性肺疾病閤併糖尿病患者中,佈地奈德霧化吸入治療3-6 mo可改善肺通氣功能,而對于血糖則無影響.
목적 탐토포지내덕무화흡입재만성조새성폐질병합병당뇨병환자중적료효급대당대사적영향.방법 60례환자수궤분성2조,포지내덕조여양계동무화흡입포지내덕혼현액2 mg,bid+이병탁추안무화흡입액500μg,bid;대조조여양계동무화흡입이병탁추안무화흡입액500μg.치료전후측정폐공능일초종용력호기용적(FEV1)、FEV1점예계치백분비(FEV1%),동맥혈양분압(PaO2),급혈당(FPG),당화혈홍단백(HbA1c).결과 57례완성시험,치료3 mo후,포지내덕조FEV1유(1.27±0.20)L승지(1.49±0.21)L(P＜0.01),FEV1%유(64.14±6.37)승지(74.76±7.62),(P＜0.01),화대조조상비차이유통계학의의(P＜0.05),치료6 mo후적FEV1、FEV1%화3 mo상비차이무통계학의의(P＞0.05).포지내덕조FPG、HbA1c치료전후차이무통계학의의(P＞0.05).결론 재만성조새성폐질병합병당뇨병환자중,포지내덕무화흡입치료3-6 mo가개선폐통기공능,이대우혈당칙무영향.
AIM To evaluate the clinical efficacy of inhaled budesonide on chronic obstructive pulmonary disease (COPD)patients with diabetes.METHODS Sixty patients with stable COPD and diabetes were randomly divided into two groups:budesonide group and control group.Both groups were received ipmtropium bromide 500μg twice a day by the inhalation of oxygen-driven.Budesonide group was also inhaled budesonide 2 mg twice a day.Forced expiratory volume in one second(FEV1),FEV1pred(FEV1%),arterial partial pressure of oxygen(PaO2),fasting plasma glucose (FPG)and glycated haemoglobin(HbA1c)were measured before and after treatment for 3,6 months.RESULTS After 3 nmnths,FEV1 of patients in budesonide group was improved from(1.27±0.20)L to(1.49±0.21)L(P＜0.01) and FEV1% was improved from(64.14±6.37)to(74.76±7.62)(P＜0.01)which was significant higher than that in control group(P＜0.05).The PaO2,FPG,HbA1c of all the matients were not significant during the test(P＞0.05).CONCLUSION The study suggests that the treatment with inhaled budesonide could improve pulmonary ventilation function without affecting the shcose metabolism.
